Introductory paper: high-dose influenza vaccine. Vaccine. 2021;39(Suppl 1):A1–5. Article PubMed Google Scholar Coleman BL, Gutmanis I, McGovern I, Haag M. Effectiveness of cell-based quadrivalent seasonal influenza vaccine: a systematic review and meta-analysis. Vaccines (Basel). 2023;11(...
The 2023–2024 US influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with cocirculation of A(H3N2) and B/Victoria viruses. We estimated vaccine effectiveness (VE) in the United States against mild-to-moderate medically attended influenza illness in the 2023–...
Influenza Vaccine Effectiveness Against Influenza-Associated Hospitalization in Hong Kong Children Aged 9 Months to 17 Years, March-June 2023 J Pediatric Infect Dis Soc, 12 (2023), pp. 586-589 CrossrefView in ScopusGoogle Scholar [7] C. Murphy, M.Y.W. Kwan, E.L.Y. Chan, J.S.C. Won...
Conclusions: This is the first study to demonstrate influenza vaccine effectiveness in children after the relaxation of strict COVID-19 measures in Japan (2023/2024). We recommend the current inactivated vaccine for preventing both influenza A and B in children, with consideration for the potential...
The global influenza vaccine market size was valued at USD 7.91 billion in 2023 and is expected to grow at a CAGR of 6.98% from 2024 to 2030
The objective of this study was to provide an estimate of influenza vaccine effectiveness (VE) against influenza-associated hospitalization in children in Hong Kong during an A(H3N2) epidemic in June-November 2023. Access through your organization Check access to the full text by signing in ...
Table 1.Characteristics of influenza-positive cases and test-negative controls, as well as influenza vaccination status of the participants included in the influenza vaccine effectiveness assessment in Beijing, China, for the 2022–2023 influenza season. ...
The global influenza vaccine market size was valued at USD 7.97 billion in 2023 and is projected to grow from USD 8.55 billion in 2024 to USD 17.77 billion by 2032, exhibiting a CAGR of 9.6% during the forecast (2024-2032). North America accounted for a market value of USD 4.28 billion...
More information:Ashley L. Fowlkes et al, Interim Effectiveness Estimates of 2023 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalizations—REVELAC-i Network, March–July 2023,MMWR. Morbidity and Mortality Weekly Report(2023).DOI: 10.15585/mmwr.mm7237e1 ...
EFFECTIVENESS OF INFLUENZA VACCINEB. J. STEPHENS, and T. J. A. LIVSEY. to be made a pharmaceutical benefit. At the present time, individual permission has to be sought from the Department of Health for each patient use, and as allergic problems are extremely common in this country, this ...